Celldex Therapeutics reported a quarterly loss of $1.18 per share, wider than the Zacks Consensus Estimate of a $1.10 loss and worse than the $0.81 loss a year ago. The results indicate a modest earnings miss and deterioration versus last year, which may pressure shares modestly but is not a major surprise.
Celldex Therapeutics reported a quarterly loss of $1.18 per share, wider than the Zacks Consensus Estimate of a $1.10 loss and worse than the $0.81 loss a year ago. The results indicate a modest earnings miss and deterioration versus last year, which may pressure shares modestly but is not a major surprise.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request a DemoOverall Sentiment
mildly negative
Sentiment Score
-0.22
Ticker Sentiment
